Roche Checkpoint Inhibitor Conquers Squamous Non-Small-Cell Lung Cancer. See Also: Some Insight on Immunotherapy and More
This content is for members
AstraZeneca Plc (AZN)
The FDA Approves AstraZeneca Checkpoint Inhibitor Imfinzi® for a Lung Cancer. A Probable Partnership Agreement Between Arbutus and Roivant
The Food and Drug Administration (FDA) approved AstraZeneca (AZN) Checkpoint inhibitor drug Imfinzi® (durvalumab) for patients with unresectable Stage III …
Acorda’s Attempted Rally. See Also: Amgen, Merck and AstraZeneca
This content is for members
A Must Read News. See Also: A New Immunotherapy Combination by Incyte and AstraZeneca
Amgen (AMGN) and Kirin Holdings (Kirin) announced an agreement upon, which Kirin-Amgen, a joint venture between the two companies, will redeem Kirin’s …
Prohost Letter #413
This content is for members
An Approval for Celgene and Two Breakthrough Designations for AstraZeneca
CELGENE Good news from Celgene (CELG) announced that the FDA approved the firm’s targeted drug Idhifa (enasidenib) for adults with relapsed or refractory …
The Value of Sangamo, Merck and AstraZeneca News
This content is for members
Prohost Letter #405
This content is for members
The FDA Manufacturing Issues. Why Portola Rallied but Is Still Way Undervalued?
MANUFACTURING ISSUES?! Why PORTOLA Stock Rallied? On Aug. 17, 2016, we learned that the FDA sent a Complete Response Letter (CRL) to Portola Pharmaceuticals …
Prohost Letter #403 Part 2
This content is for members
Is Prohost Still Cautious About Investing in Clovis Oncology?
This content is for members
Gilead and Genmab Agreement. A Quick Look at Moderna
This content is for members
Coming from AstraZeneca and Juno: News That Makes a Big Difference
This content is for members
Disrupting the Capability of Cancer Cells to Repair Their Damaged DNA. Underestimated Biotech Firms
This content is for members
Prohost Letter #395
This content is for members